checkpoint blockade immunotherapy
Nanotopography-based lymphatic delivery for improved anti-tumor responses to checkpoint blockade immunotherapy
... gravity) to regional LN basins. Following transport through chains of downstream LNs via afferent and efferent lymphatic vessels, lymph is deposited into the blood vasculature via the subclavian vein [7]. Monoclonal ...
12
Integrin αvβ3-targeted radionuclide therapy combined with immune checkpoint blockade immunotherapy synergistically enhances anti-tumor efficacy
... However, only 15-40% of patients respond to anti-PD1/PD-L1 mAbs; therefore, the population of patients benefiting from ICB therapy is still rather narrow [1]. As such, researchers must elucidate how to combine ICB ...
13
Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma
... classical (CL), and (4) mesenchymal (MES) [32]. These four subtypes have distinct cellular and molecular charac- teristics in their respective microenvironments. For example, NF1 and TP53 deletions and mutations were ...
13
Immune checkpoint blockade in small cell lung cancer: is there a light at the end of the tunnel?
... immune checkpoint block- ...CTLA-4 blockade indicate that a high mutational burden correlated with a sustained clinical bene fi ...of checkpoint blockade is that tumour antigens, as a ...
7
Shining Gold Nanostars: From Cancer Diagnostics to Photothermal Treatment and Immunotherapy
... of checkpoint blockade immunotherapy with GNS-mediated photothermal therapy offers the promise to address one of the most challenging problems in the treatment of metastatic cancer and ultimately ...
8
<p>Past, Present, and Future of Anticancer Nanomedicine</p>
... tumor immune response with cytokines such as TNF- α , activating T cells to attack tumor cells, and inducing M1- type macrophage repolarization. 251–253 NK cell membrane- decorated NPs (NK-NPs) can improve NK cell ...
25
Emerging strategies for combination checkpoint modulators in cancer immunotherapy
... A second requirement for optimal combinatorial immuno- therapy is the identification of sensitive biomarkers for guidance toward individuals who would benefit most from immune check- point modulators and minimize ...
11
Cytotoxic T lymphocyte antigen 4 and immune checkpoint blockade
... The ability to induce a higher rate of durable responses with ipilimumab is dependent upon immune activation, suggesting that combinations with other immune modulators may increase effi- cacy. The combination of IL-2 and ...
8
Tumor control with PD-1 inhibition in a patient with concurrent metastatic melanoma and renal cell carcinoma
... survival when compared to ipilimumab in advanced mel- anoma [6]. Strikingly, as opposed to the relatively modest anti-tumor activity of ipilimumab outside of melanoma, PD-1 pathway inhibition is efficacious against a ...
5
Systemic inflammation in a melanoma patient treated with immune checkpoint inhibitors—an autopsy study
... Other findings included a bone marrow lymphocy- tosis and hepatic mononuclear and histiocytic infil- trates. Hepatic toxicity and elevation of liver enzymes has been described as a mostly low-grade irAE in pa- tients ...
8
Grover’s-like drug eruption in a patient with metastatic melanoma under ipilimumab therapy
... immunological checkpoint surface molecule cytotoxic T-lymphocyte- associated antigen 4 (CTLA-4), has been shown to im- prove the overall survival of patients with metastatic melanoma in clinical trials ...
5
Cancer therapeutic implications of microRNAs in the regulation of immune checkpoint blockade
... The human immune system is an intricate cellular net- work, which has developed to protect us against micro- organism invasion but can also eliminate malignant cells in our body. Thereby, cancer is considered as another ...
6
A New VISTA on combination therapy for negative checkpoint regulator blockade
... Blockade of PD-1/PD-L1 axis expanding boundaries Similar to CTLA-4, Programmed cell death 1 (PD-1) is not expressed on naïve or memory T cells but is expressed on activated and exhausted T cells [25, 26]. PD-1 has ...
7
Therapeutic challenges and current immunomodulatory strategies in targeting the immunosuppressive pancreatic tumor microenvironment
... immune checkpoint therapy by increasing infil- tration of CD4 + T cells and NK cells, while decreasing the percentage of MDSCs; at the same time, it also enhanced the accumulation of immunotherapeutic antibody in ...
23
C3d regulates immune checkpoint blockade and enhances antitumor immunity
... immune checkpoint inhibitors can facilitate the emergence of protective immunity and control of malignancies (1, 2) confirm the idea that immune surveillance can provide a primary defense against malignant ...
13
Sitravatinib potentiates immune checkpoint blockade in refractory cancer models
... Sitravatinib enhances the efficacy of PD-1 blockade. To test the combinatorial effect of sitravatinib and PD-1 blockade, we treated cohorts of KLN205 or E0771 tumor-bearing mice with the compound with or ...
11
Challenges and opportunities for checkpoint blockade in T-cell lymphoproliferative disorders
... Lenalidomide is an immunomodulatory derivative (IMiD) with pleiotropic immunomodulatory effects and clinical activity in many hematologic malignancies. Lenalidomide promotes natural killer (NK) cell function [62, 63], ...
10
An unsuspected complication with immune checkpoint blockade: a case report
... irAEs have been described in almost every organ, includ- ing endocrine dysfunction. In a retrospective study con- ducted by Villa et al. [9], including patients who were treated with both anti-CTLA-4 (ipilimumab) and ...
5
Increased vessel perfusion predicts the efficacy of immune checkpoint blockade
... Immune cell responses in general, and T cell activation in par- ticular, have been used to evaluate the effectiveness of ICB in both preclinical and clinical studies to date. However, because of the immunosuppressive ...
13
Combination of radiotherapy and vaccination overcomes checkpoint blockade resistance
... limiting step for immune-mediated tumor regression. We demonstrate that IR, a clinically applicable modality for the treatment of pancreatic cancer, also stimulates T cell infiltration into tumors to sensitize pancreatic ...
13